Realm - Randomized, Observational Study of Entecavir To Assess Long-Term Outcomes Associated with Nucleoside/nucleotide Monotherapy For Patients with Chronic Hiv Infection Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 9 years ago on Monday, June 16, 2014, according to the United State Patent & Trademark Office
Word Mark Realm - Randomized, Observational Study of Entecavir to Assess Long-Term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic Hiv Infection
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 85041166
Status Date Monday, June 16, 2014
Filing Date Monday, June 16, 2014
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
BRISTOL-MYERS SQUIBB COMPANY
Trademarks Dept. - Room D33-05
P.O. Box 4000
Princeton NJ 08648-4000

Case File Statements

Disclaimer with Predetermined Text "Randomized, Observational Study of Entecavir to Assess Long-Term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic Hiv Infection"
Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Saturday, May 22, 2010
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.